GI Innovation和 GI Biome凭借GI-102和GIB-7组合疗法的抗衰老潜力，晋级XPRIZE Healthspan半决赛-动脉网

GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy

CISION 等信源发布 2025-05-13 09:21



可切换为仅中文







GI Innovation and GI Biome have

GI Innovation 和 GI Biome 公司拥有

been selected as a Top 40

被评为前40名

semi-

半-

finalist in

入围者

the XPRIZE Healthspan competition

XPRIZE健康寿命竞赛

among 600 registered teams from 58 countries

在来自58个国家的600支注册队伍中

Selected as one of 8 teams to pitch at the XPRIZE Investor Summit in

被选为在XPRIZE投资者峰会上展示的8个团队之一

New York

纽约

The team is now competing for

团队现在正在竞争

one of

其中之一

the largest prize

最大奖项

pool

池子

in the history of

在...的历史中

XPRIZE

SEOUL, South Korea

韩国，首尔

，

May 12, 2025

2025年5月12日

/PRNewswire/ --

GI Innovation

胃肠创新

, a South Korean biotech company, announced on

，一家韩国生物技术公司，于

May 13

5月13日

that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company GI Biome.

它已被选为XPRIZE Healthspan竞赛的半决赛选手，与其姐妹公司GI Biome合作。

继续阅读

Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony

XPRIZE Healthspan奖项颁奖典礼上的第一个里程碑获奖者

The XPRIZE Healthspan semi-finals ceremony is taking place in

XPRIZE Healthspan半决赛颁奖典礼正在举行

New York

纽约

from

从

May 12 to 14

5月12日至14日

, with the top 40 semi-finalist teams out of more than 600 registered teams among 58 countries invited. The company has not only advanced to the semi-finals but has also been selected as one of 8 teams among the 40 semi-finalists to earn an exclusive opportunity to present its vision and innovations to high-profile, institutional global investors..

，从58个国家的600多支注册队伍中邀请进入前40名的半决赛队伍。该公司不仅进入了半决赛，还被选为40支半决赛队伍中的8支之一，获得了向高知名度的全球机构投资者展示其愿景和创新的独家机会。

XPRIZE, a U.S.-based nonprofit foundation, is the recognized global leader in designing and executing large-scale competitions to solve humanity's greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. .

XPRIZE是一家总部位于美国的非营利基金会，是设计和执行大规模竞赛以解决人类最大挑战的全球公认领导者。30多年来，我们独特的模式实现了众包创新的民主化，并推动了科学上可扩展的解决方案，加速迈向更加公平和富足的未来。

Semi-finalists are selected by an expert committee using rigorous guidelines and advancement into this elite group is seen as recognition of exceptional scientific vision and execution.

半决赛选手由专家委员会按照严格的指导原则选出，进入这一精英团体被视为对卓越科学视野和执行力的认可。

The XPRIZE Healthspan competition, in which the joint GI Innovation - GI Biome team is competing, aims to discover breakthrough treatments that can slow or prevent age-related degeneration. The competition offers a record-breaking total prize pool of approximately USD

XPRIZE Healthspan竞赛，GI Innovation - GI Biome联合团队正在参与其中，旨在发现能够减缓或预防与年龄相关的退化的突破性疗法。该竞赛提供了创纪录的总奖金池，约为美元。

$101 million

1.01亿美元

。

Selected as a semi-finalist team, GI Innovation will receive a prize of USD

被选为半决赛团队，GI Innovation将获得美元奖励

$250,000

250,000美元

to support the next clinical trial stage. Only the top 10 teams from the semi-finals round will advance to the grand finals.

以支持下一阶段的临床试验。只有从半决赛中脱颖而出的前 10 支队伍才能晋级总决赛。

'Anti-Aging' Strategy with Immune Booster GI-102 and Microbiome-Based GIB-7 Combination

使用免疫增强剂GI-102和基于微生物组的GIB-7组合的“抗衰老”策略

The GI Innovation-GI Biome joint team proposed a combination therapy consisting of GI-102, an immune-boosting drug, and GIB-7, a microbiome-based synbiotic, as a novel anti-aging approach.

GI Innovation-GI Biome联合团队提出了一种组合疗法，包含免疫增强药物GI-102和基于微生物组的合生元GIB-7，作为一种新型抗衰老方法。

Clinical studies have shown that GI-102 potently activates CD8+ T cells and NK cells at high doses, allowing those immune cells to safely attack a range of tumor types including melanoma, kidney, lung and bladder cancers. However, at a low dose, it selectively expands and activates NK cells, which are critical for clearing senescent cells and cellular debris, playing a vital role in delaying aging and maintaining physiological functions.

临床研究显示，GI-102 在高剂量下能有效激活 CD8+ T 细胞和 NK 细胞，使这些免疫细胞能够安全地攻击多种肿瘤类型，包括黑色素瘤、肾癌、肺癌和膀胱癌。然而，在低剂量下，它选择性地扩增并激活对清除衰老细胞和细胞碎片至关重要的 NK 细胞，这些细胞在延缓衰老和维持生理功能方面发挥着关键作用。

Based on this mechanism, GI Innovation is pursuing the use of low-dose GI-102 as an NK cell enhancer..

基于这种机制，GI Innovation公司正在追求将低剂量的GI-102用作NK细胞增强剂。

GIB-7 is a premium synbiotic developed using GI Biome's proprietary Microbiome+ Herbal Therapy platform. It combines three patented probiotic strains with herbal ingredients. Clinical trials in elderly volunteers at Seoul

GIB-7 是一款采用 GI Biome 专有的微生物组+草本疗法平台开发的优质合生元产品。它结合了三种获得专利的益生菌菌株和草本成分。在首尔进行的老年志愿者临床试验中

National University

国立大学

Hospital have already been completed. In an aging mouse model, GIB-7 elicited an increase in beneficial gut microbiota, improved regulation of circadian rhythm, and improved muscle strength.

医院已经完工。在衰老小鼠模型中，GIB-7 引发了有益肠道菌群的增加，改善了昼夜节律的调节，并增强了肌肉力量。

'We entered this competition with the goal of winning, and it is a great honor to have passed the first gateway, highlighting the scientific innovation of both GI Innovation and GI Biome,' said Dr.

“我们参加这场比赛的目标就是获胜，通过第一个关口真是莫大的荣幸，这突显了GI Innovation和GI Biome的科学创新，”博士说道。

Myoung-Ho Jang

张明浩

, CEO and Founder of GI Innovation. 'The upcoming clinical trial will be conducted in collaboration with Dr. Katherine Samaras, a key opinion leader in anti-aging research at the Garvan Institute of Medical Research in

，GI Innovation的首席执行官兼创始人。“即将进行的临床试验将与加文医学研究所抗衰老研究领域的关键意见领袖凯瑟琳·萨马拉斯博士合作进行。

Australia

澳大利亚

. Through this competition, we will do our utmost to realize our global vision of progressing from treatment to prevention.'

通过这次竞赛，我们将尽最大努力实现我们从治疗到预防的全球愿景。

SOURCE GI Innovation

来源 GI 创新

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+